SCHEMBL29630293

SCHEMBL29630293

[218Rn]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1048121 1.00
Methane SCHEMBL23088734 0.00
Hydrogen Sulfide SCHEMBL23805181 0.00
SCHEMBL23528133 0.00
SCHEMBL23358113 0.00
SCHEMBL23462252 0.00
SCHEMBL25435013 0.00
SCHEMBL23462141 0.00
Potassium Ion SCHEMBL23462035 0.00 CA4 (0.50)
SCHEMBL23462036 0.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12638602-B2 Metal organic framework particles as radioisotope detectors ARIZONA BOARD OF REGENTS OF BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2026-05-26 US claimed
EP-4731270-A1 COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR The Regents of The University of California (US) 2026-04-29 EP claimed
US-20250051478-A1 scFv and Antibodies with Reduced Multimerisation Y-Mabs Therapeutics, Inc. 2025-02-13 US claimed
WO-2024263637-A1 COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-26 WO claimed
EP-4448565-A1 SCFV AND ANTIBODIES WITH REDUCED MULTIMERISATION Y-Mabs Therapeutics, Inc. (US) 2024-10-23 EP claimed
US-20240280712-A1 METAL ORGANIC FRAMEWORK PARTICLES AS RADIOISOTOPE DETECTORS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2024-08-22 US claimed
CN-118369339-A ScFv and antibodies with reduced multimerization Y-单克隆抗体制药有限公司 2024-07-19 CN claimed
WO-2023110045-A1 SCFV AND ANTIBODIES WITH REDUCED MULTIMERISATION Y-Mabs Therapeutics, Inc. (US) 2023-06-22 WO claimed
WO-2023069767-A1 METAL ORGANIC FRAMEWORK PARTICLES AS β EMISSION DETECTORS IN AQUEOUS SYSTEMS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2023-04-27 WO claimed
EP-4168450-A2 CD38 ANTIBODIES FOR THE TREATMENT OF HUMAN DISEASES Y-Mabs Therapeutics, Inc. (US) 2023-04-26 EP claimed
US-12638602-B2 Metal organic framework particles as radioisotope detectors ARIZONA BOARD OF REGENTS OF BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2026-05-26 US disclosed
EP-4731270-A1 COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR The Regents of The University of California (US) 2026-04-29 EP disclosed
US-20250325715-A1 RADIOLABELED LIPOSOMES AND METHODS OF USE FOR TREATING LEPTOMENINGEAL METASTASES PLUS THERAPEUTICS, INC. (US) 2025-10-23 US disclosed
US-20250041410-A1 Formulations Comprising a SADA Complex Y-Mabs Therapeutics, Inc. 2025-02-06 US disclosed
CN-119301130-A Radiolabeled liposomes and methods of use for treating leptomeningeal metastases 加法治疗公司 2025-01-10 CN disclosed
CN-109655858-B Multi-electrode measuring instrument pair for improving radon exhalation rate 218 Po collection efficiency measurement cavity and method 衡阳师范学院 2022-08-12 CN disclosed
CN-109307880-B Multiple electrode positive charging 218 Po collection efficiency measurement cavity and method 衡阳师范学院 2022-08-12 CN disclosed
CN-109254313-B Multiple detectors for increasing positive charge 218 Po collection efficiency measurement cavity and method 衡阳师范学院 2022-08-12 CN disclosed
WO-2022120226-A1 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-06-09 WO disclosed
US-20220152228-A1 COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADE WASHINGTON UNIVERSITY (US) 2022-05-19 US disclosed